Search results
Showing 2071 to 2085 of 8933 results
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
In development Reference number: GID-TA10249 Expected publication date: TBC
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]
In development Reference number: GID-TA10250 Expected publication date: TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]
In development Reference number: GID-TA10251 Expected publication date: TBC
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278]
Awaiting development Reference number: GID-TA10279 Expected publication date: TBC
Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]
Awaiting development Reference number: GID-TA10431 Expected publication date: TBC
Awaiting development Reference number: GID-TA10439 Expected publication date: TBC
In development Reference number: GID-TA10446 Expected publication date: TBC
Awaiting development Reference number: GID-TA10453 Expected publication date: TBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]
In development Reference number: GID-TA10606 Expected publication date: TBC
Awaiting development Reference number: GID-TA10657 Expected publication date: TBC
Awaiting development Reference number: GID-TA10665 Expected publication date: TBC
Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]
Awaiting development Reference number: GID-TA10683 Expected publication date: TBC
Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]
Awaiting development Reference number: GID-TA10684 Expected publication date: TBC
Awaiting development Reference number: GID-TA10685 Expected publication date: TBC
In development Reference number: GID-TAG509 Expected publication date: 28 September 2016